Hemolytic transfusion reaction in sickle cell disease (HTRSCD)
Not for Routine Use
When screening requests for approval, the following information may be taken into account as there is some evidence for IG to be considered as an option.
Order Number: H19-HTRSCD
| Recommendations | IVIG may be considered among the options for treatment of serious, life-threatening, delayed hemolytic transfusion reactions in SCD patients. |
| Dose/Frequency of Administration | No recommended dose or duration listed; however, expert panel recommends up to 2 g/kg divided over 2 to 5 consecutive days |